GSK for You

GlaxoSmithKline wants to help you to get the drugs you need, even if you don't take our medicines. To learn more about how to save on medicines and GlaxoSmithKline's available drug savings programs, call us toll-free Monday through Friday at 1-866-GSK-FOR-U (1-866-475-3678) between 8:00 am and 8:00 pm Eastern Time, or contact us online

GlaxoSmithKline has a challenging and inspiring mission: to improve the quality of human life by enabling people to do more, feel better, and live longer. This mission gives us the purpose to develop medicines that help millions of people around the world.

But being a leader brings responsibility. We know that access to medicines is an important issue in this country, because many people don't have prescription drug coverage. In response, GlaxoSmithKline has developed a number of patient assistance programs and discount cards to provide prescription drug help to patients who take our medicines.

GSK assistance programs

Our patient assistance programs provide prescription medicines to low-income, uninsured patients free or at very low cost. GlaxoSmithKline operates several programs, including:

Commitment to Access, which covers cancer treatments
Bridges to Access, which covers other medicines for outpatients
GSK Access, which provides free GlaxoSmithKline medicines to people enrolled in a Medicare drug plan who meet program requirements

GlaxoSmithKline was the first pharmaceutical company in the US to offer a card providing prescription drug help to low-income seniors and disabled people. In 2002, GlaxoSmithKline and six other pharmaceutical companies established the Together Rx card, which provided participating company's discounts on over 100 prescription medicines for low-income senior citizens who are eligible for Medicare.

Today, we're committed to improving the quality of human life and contributing to a better future for all. That's why we're working to help people who need prescription drug help. Meet members of the GlaxoSmithKline team who are helping callers every day with their prescription drug coverage questions and concerns. To learn more about GlaxoSmithKline, visit our company site.

See the full Prescribing Information for LEXIVA

LEXIVA® (fosamprenavir calcium)

Indication and Usage:

LEXIVA is indicated in combination with other antiretroviral agents for the treatment of HIV infection in adults.

For PI-experienced patients, the following points should be considered:

The protease inhibitor-experienced patient study was not large enough to reach a definitive conclusion that LEXIVA/ritonavir and lopinavir/ritonavir are clinically equivalent
Once-daily administration of LEXIVA plus ritonavir is not recommended for protease inhibitor-experienced patients

Important Safety Information

LEXIVA is contraindicated in patients with previously demonstrated clinically significant hypersensitivity to any of the components of this product or to amprenavir
Hyperglycemia, new onset or exacerbations of diabetes mellitus, and spontaneous bleeding in hemophiliacs have been reported with protease inhibitors
Immune reconstitution syndrome has been reported in patients treated with combination antiretroviral therapy, including LEXIVA. During the initial phase of combination antiretroviral treatment, patients whose immune systems respond may develop an inflammatory response to indolent or residual opportunistic infections (such as Mycobacterium avium infection, cytomegalovirus, Pneumocystis jirovecii pneumonia [PCP], or tuberculosis), which may necessitate further evaluation and treatment
Redistribution/accumulation of body fat have been observed in patients receiving antiretroviral therapy. The causal relationship, mechanism, and long-term consequences of these events are currently unknown
LEXIVA should be used with caution in patients with a known sulfonamide allergy
Severe or life-threatening skin reactions were reported in <1% of 700 patients treated with LEXIVA in clinical studies, including one case of Stevens-Johnson syndrome
Skin rash (all grades, without regard to causality) occurred in approximately 19% of patients treated with LEXIVA in the pivotal efficacy studies. This led to the discontinuation of LEXIVA in <1% of patients
Treatment with LEXIVA/r has resulted in increases in the concentration of triglycerides. Triglyceride and cholesterol testing should be performed prior to initiating therapy with LEXIVA and at periodic intervals during therapy
Caution should be exercised when administering LEXIVA to patients with hepatic impairment, including those with hepatitis B or C or marked elevation in transaminases prior to treatment. Increased AST/ALT monitoring should be considered in these patients
The most common grade 2-4 drug-related adverse events were diarrhea, nausea, vomiting, headache, and rash

DRUG INTERACTIONS

LEXIVA is contraindicated with ergot derivatives, cisapride, pimozide, midazolam, and triazolam. If LEXIVA is coadministered with ritonavir, flecainide and propafenone are also contraindicated
Caution should be used when coadministering medications that are substrates, inhibitors, or inducers of CYP3A4, or potentially toxic medications that are metabolized by CYP3A4
Serious and/or life-threatening drug interactions could occur between LEXIVA and amiodarone, lidocaine (systemic), tricyclic antidepressants, and quinidine. Concentration monitoring of these agents is recommended if these agents are used concomitantly with LEXIVA
LEXIVA should not be coadministered with rifampin, St. John's wort, lovastatin, simvastatin, or delavirdine
Particular caution should be used when prescribing phosphodiesterase (PDE-5) inhibitors for erectile dysfunction (eg, sildenafil or vardenafil) in patients receiving LEXIVA
This list of potential drug interactions is not complete
Concomitant use of LEXIVA and oral contraceptives is not recommended. LEXIVA taken with oral contraceptives may alter hormonal levels. LEXIVA plus ritonavir taken with oral contraceptives may result in clinically-significant hepatic transaminase elevations. Therefore, alternative methods of non-hormonal contraception are recommended